Listar Departamento de Anatomía y Anatomía Patológica Comparadas y Toxicología por autor "abc9d7ca-2ecd-489c-b816-6ec08fdad0d5"

Mostrando ítems 1-9 de 9

    • Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 

      Aurilio, Gaetano; Cimadamore, Alessia; Mazzucchelli, Roberta; López-Beltrán, Antonio; Verri, Elena; Scarpelli, Marina; Massari, Francesco; Cheng, Liang; Santoni, Matteo; Montironi, Rodolfo (MDPI, 2020)
      Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is ...

    • Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma 

      Mollica, Veronica; Rizzo, Alessandro; Montironi, Rodolfo; Cheng, Liang; Giunchi, Francesca; Schiavina, Riccardo; Santoni, Matteo; Fiorentino, Michelangelo; López-Beltrán, Antonio; Brunocilla, Eugenio; Brandi, Giovanni; Massari, Francesco (MDPI, 2020)
      Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year ...

    • Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy 

      Cimadamore, Alessia; Gasparrini, Silvia; Massari, Francesco; Santoni, Matteo; Cheng, Liang; López-Beltrán, Antonio; Scarpelli, Marina; Montironi, Rodolfo (MDPI, 2019)
      Liquid biopsy, based on the circulating tumor cells (CTCs) and cell-free nucleic acids has potential applications at multiple points throughout the natural course of cancer, from diagnosis to follow-up. The advantages of ...

    • Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer 

      López-Beltrán, Antonio; Cimadamore, Alessia; Blanca, Ana; Massari, Francesco; Vau, Nuno; Scarpelli, Marina; Cheng, Liang; Montironi, Rodolfo (MDPI, 2021)
      A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the ...

    • Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing 

      López-Beltrán, Antonio; López-Ríos, Fernando; Montironi, Rodolfo; Wildsmith, Sophie; Eckstein, Markus (MDPI, 2021)
      Immuno-oncology (IO) agents (anti–programmed cell death 1 (PD-1) and anti–programmed cell death-ligand 1 (PD-L1)) are approved as first- and second-line treatments for metastatic UC. PD-L1 expression levels in UC tumors ...

    • New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 

      Aurilio, Gaetano; Cimadamore, Alessia; Santoni, Matteo; Nolé, Franco; Scarpelli, Marina; Massari, Francesco; López-Beltrán, Antonio; Cheng, Liang; Montironi, Rodolfo (MDPI, 2020)
      Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in ...

    • Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 

      Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Scarpelli, Marina; Montironi, Rodolfo; Massari, Francesco (Frontiers, 2018)
      Management of localized and advanced prostate cancer benefits from several therapeutic options with a surprising improvement in terms of clinical outcome. The selection of patients more likely to benefit from a specific ...

    • Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor 

      Mollica, Veronica; Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Scarpelli, Marina; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Battelli, Nicola; Montironi, Rodolfo; Massari, Francesco (MDPI, 2019)
      The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with ...

    • Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer 

      Cimadamore, Alessia; Aurilio, Gaetano; Nolé, Franco; Massari, Francesco; Scarpelli, Marina; Santoni, Matteo; López-Beltrán, Antonio; Cheng, Liang; Montironi, Rodolfo (MDPI, 2020)
      Current developments in the treatment of genitourinary tumors underline the unmet clinical need for biomarkers to improve decision-making in a challenging clinical setting. The detection of circulating tumor cells (CTCs) ...